Key facts
- It has raised $8.6M; the latest was Seed Round ($8.6M) in Dec 2025.
- Notable investors include Highlight Capital, ALK-Abello, Forty51 Ventures, Lichtsteiner Foundation, Venturelab.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Allegria Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Allegria Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Allegria Therapeutics
Provider of biotech research services intended to improve the treatment landscape of therapeutics. The company offers research and development focused on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden worldwide, enabling patients to lead a healthy lifestyle.
- Sector
- Healthcare
- HQ
- Basel, Switzerland
- Founded
- 2024
- Employees
- 2
- Website
- allegriatx.com/
- Ownership
- Privately Held (backing)
Allegria Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Allegria Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Allegria Therapeutics in its N-PORT filings yet. We sweep new filings monthly.